Abstract
Background: With the rising prevalence of critical limb ischemia (CLI), the pedal-plantar loop technique and retrograde access may be needed to increase interventional success.
Case Report: A 63-year-old female with severe peripheral artery disease presented with a 2-month nonhealing wound on the dorsum of her left foot despite wound care. We inserted a 65-cm Destination Guiding Sheath and crossed the right superficial femoral artery (SFA) chronic total occlusion (CTO) that we initially treated with a 4.0-mm Ultraverse balloon. We attempted unsuccessfully to cross the distal anterior tibial artery into the dorsalis pedis artery. We obtained antegrade access of the posterior tibial artery at the level of the ankle with a 2.9-French Cook pedal access kit. We inserted a 90-cm CXI catheter with a 0.014 Fielder XT wire and used the lateral plantar artery as a conduit to cross the dorsalis pedis artery and distal anterior tibial artery CTO with retrograde wire manipulation via lateral plantar artery. Finally, we performed distal anterior tibial and dorsalis pedis CTO balloon angioplasty with a 2.5 × 220-mm Ultraverse balloon and performed SFA percutaneous transluminal angioplasty and stenting with a 7.0 × 120-mm Zilver PTX stent, postdilated with a 6.0-mm Ultraverse balloon. We successfully established in-line flow to the foot with 3-vessel runoff. The patient's wound healed in a month.
Conclusion: Retrograde pedal access can improve the success rate of recanalization of below-the-knee disease in patients with CLI.
INTRODUCTION
The prevalence of critical limb ischemia (CLI)—characterized by multilevel peripheral artery disease (PAD)—is increasing, and below-the-knee disease is especially difficult to treat.1,2 To avoid the major economic cost, disability, and mortality associated with CLI and amputation, an endovascular first approach is recommended.3,4
The pedal-plantar loop technique and retrograde access, together with an antegrade ipsilateral common femoral artery (CFA) approach, can increase the success rate of revascularization and the clinical outcome of below-the-knee disease, improving the wound-healing process.5 Tibiopedal access is increasingly being used as first-line approach because of increases in expertise, improved tools, and reduced complication rates in patients who are poor candidates for antegrade access.6-8
We present the case of a patient with a 2-month history of a nonhealing foot wound that responded to revascularization of the pedal arch.
CASE REPORT
A 63-year-old female with a history of coronary artery disease, hyperlipidemia, hypertension, borderline diabetes, obesity, and severe PAD (Rutherford grade V, Fontaine stage IV) was referred by podiatry for a 2-month nonhealing wound on the dorsum of her left foot despite aggressive wound care. The patient's procedural history included revascularization of the right superficial femoral artery (SFA) for CLI and chronic total occlusion (CTO) of residual left mid-SFA, distal anterior tibial artery, and dorsalis pedis artery (Figure 1).
Preintervention angiogram of residual left superficial artery, distal anterior tibial artery, and dorsalis pedis artery chronic total occlusion.
Ideally, we would have obtained ipsilateral antegrade CFA access for adequate support, but obesity posed a high risk of bleeding. We obtained contralateral right CFA access using a micropuncture kit and then upsized to a 6-French (Fr) sheath. We administered heparin after the 6-Fr 65-cm Destination Guiding Sheath (Terumo Corporation) was exchanged. Next, we inserted a 135-cm NaviCross Support Catheter (Terumo Corporation) with a 0.035 Glidewire Advantage wire (Terumo Corporation) that crossed the SFA CTO. We initially treated the SFA CTO with a 4.0-mm Ultraverse balloon (BD). We telescoped an angled 150-cm CXI Support Catheter (Cook Medical) with a 0.014 Fielder XT wire (Asahi Intecc Co, Ltd) to cross the proximal segment of the anterior tibial artery CTO. We were not able to advance the catheter or the wire past the distal anterior tibial artery into the dorsalis pedis artery because of inadequate support and equipment length.
We obtained ultrasound-guided antegrade access of the posterior tibial artery at the level of the ankle with a 2.9-Fr Cook pedal access kit (Cook Medical) (Figure 2). We inserted a 90-cm CXI catheter (Cook Medical) with a 0.014 Fielder XT wire and used the lateral plantar artery as a conduit to cross the dorsalis pedis and distal anterior tibial CTO with retrograde wire manipulation (Figure 3A). Finally, we performed balloon angioplasty of the anterior tibial artery and dorsalis pedis artery with a 2.5 × 220-mm Ultraverse balloon and performed SFA percutaneous transluminal angioplasty and stenting with a 7.0 × 120-mm Zilver PTX stent (Cook Medical) postdilated with a 6.0-mm Ultraverse balloon at the end of the case (Figure 3B).
Antegrade access of the posterior tibial artery at the level of the ankle was obtained with 2.9-French Cook pedal access kit.
(A) Crossing the dorsalis pedis artery, and anterior tibial artery, chronic total occlusion with retrograde wire manipulation via the lateral plantar artery during the intervention. (B) Superficial femoral artery percutaneous transluminal angioplasty and stenting with 7.0 × 120-mm Zilver PTX stent during the intervention.
Postprocedural imaging showed a patent SFA with 3-vessel runoff (Figure 4). Right CFA access hemostasis was achieved with a Perclose ProGlide vascular closure device (Abbott Laboratories). Hemostasis of the posterior tibial access was obtained with manual pressure. The patient's wound healed in 1 month (Figure 5).
(A) Three-vessel runoff to the foot. (B) Patent pedal-plantar loop postintervention.
(1) Preintervention dorsal foot wound. (2-6) Wound recovery from 1 week postintervention to 1 month postintervention.
DISCUSSION
Because of lack of awareness of PAD among patients and physicians and increasing comorbidities such as diabetes, the prevalence of CLI characterized by multilevel PAD is rising. More than 1.3% of patients with lower extremity PAD develop CLI, a severe clinical manifestation of PAD that is associated with an annual mortality rate of approximately 20%.9 The occurrence of CLI significantly worsens clinical outcomes in patients with PAD and adversely affects health care spending.10 Without proper intervention, CLI represents a considerable burden on the US health care system and individual morbidity and mortality and causes reduced health-related quality of life, particularly as the overall life expectancy increases.11,12
Advances in endovascular techniques, devices, adjuvant treatments, and operator experience have led to endovascular therapy being the preferred treatment of PAD and CLI.4 Use of tibiopedal access is increasing as a first-line approach because of increased expertise, improved tools, and reduced complication rates in patients who are poor candidates for antegrade access and for the treatment of patients with PAD suffering from claudication (Rutherford grades II and III) that has not yet progressed to CLI (Rutherford grades IV, V, and VI).6,8 In a retrospective study of 23 patients in 2014, 95% achieved a successful outcome—ability to cross lesion and achieve posttreatment stenosis <30%—using tibiopedal access with few complications.11
Tibiopedal access increases the success of staying within the true lumen, reduces overuse of costly CTO crossing tools and reentry tools, dramatically reduces fluoroscopy times, reduces bleeding risk, improves control because of proximity of the target lesion to the access, and reduces time to discharge.13,14 Very few complications have been reported in the literature, principally access-site thrombosis, which is usually salvaged and rarely needs surgery.15,16 Revascularization of the pedal arch has been shown to improve wound healing, especially in patients with diabetes.17
In addition to early revascularization, optimum medical therapy with a statin, antiplatelet therapy, and a multidisciplinary approach can improve outcomes. Procedurally, ultrasound-guided pedal loop access reduces vascular complications and radiation exposure to both patient and operator, compared to traditional access without ultrasound. Heparin is dosed using 80 U/kg with a goal activated clotting time of 250 to 300 seconds throughout the case. Because of multiple comorbidities such as chronic kidney disease and congestive heart failure, many patients need a staged approach—2 or more shorter procedures intervening on different segments or different limbs spanning a couple of weeks to months. Iodinated contrast agents and intravenous fluids need to be cautiously given, taking into consideration the Mehran score and the maximum allowable contrast dose for patients with chronic kidney disease18,19 or heart failure with presumed high-normal to high left ventricular end-diastolic pressure, using modified POSEIDON (Prevention of Contrast Renal Injury With Different Hydration Strategies) criteria to administer 1.5 mL/kg of body weight for 4 hours postintervention.20 Finally, a team-based approach that includes podiatrists; wound care specialists; interventional cardiologists trained to perform endovascular procedures; primary care doctors; physical therapists; endocrinologists for diabetes care; and plastic, orthopedic, and vascular surgeons is imperative to address the complexity of patients with CLI.
CONCLUSION
This case demonstrates that the pedal-plantar loop technique may increase the success rate of revascularization of below-the-knee disease in patients with CLI.
This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.
ACKNOWLEDGMENTS
Portions of this paper were presented as a poster at the Louisiana American College of Cardiology annual meeting on September 21, 2019. The authors have no financial or proprietary interest in the subject matter of this article.
- ©2021 by the author(s); Creative Commons Attribution License (CC BY)
©2021 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
REFERENCES
In this issue
Jump to section
Cited By...
- No citing articles found.